Gravel suggests that the elevated IL-10 concentrations found in microglia during the initial stages of ALS serve as a regulatory and compensatory adaptive immune strategy, functioning as a non-neuronal factor influencing the clinical initiation of the disease [58] and a promising therapeutic strategy in halting microglia activation and associated effects in MN degeneration. This evidence concerns the gene IL10 and amyotrophic lateral sclerosis.